Significance: Leucine-rich glioma-inactivated 1 (LGI1) is a secreted neuronal protein associated in a multiprotein complex with Kv1 channels. Natural mutations in this protein are found in the early-adulthood–onset disorder “autosomal dominant epilepsy with auditory features” and animal models with Lgi1 genetic deletion display spontaneous seizures. We investigated the potential link between LGI1 depletion and intrinsic neuronal excitability. We found that LGI1 determines neuronal excitability in CA3 pyramidal neurons through the control of axonal Kv1-channel expression. Genetic deletion of Lgi1 induces a robust diminution in Kv1 channels, especially in axons where they colocalize with LGI1, very likely contributing to epileptogenesis. These results strongly suggest that LGI1 controls neuronal excitability by regulating Kv1-channel expression.
20 August 2019 in Proceedings of the National Academy of Sciences
Significance: Botulism is induced by Clostridium botulinum neurotoxins (BoNTs). At neuromuscular junctions, BoNT/B binds to dual receptors: a plasma membrane resident polysialoganglioside and synaptotagmin, a synaptic vesicle protein transiently inserted in neuronal membranes upon exocytosis. It is widely thought that BoNT binds initially to gangliosides and that this binary complex then diffuses to interact with synaptotagmin. Here, we show that the true BoNT/B receptor is the preassembled GT1b–SYT complex and that the α-helical structure of the BoNT/B binding domain of synaptotagmin found in previous structural studies is induced by the ganglioside before it ever meets the toxin. BoNT/B thus exploits a preexisting protein–glycolipid complex of yet unknown physiological function.
Leucine-rich Glioma-Inactivated protein 1 (LGI1) is expressed in the central nervous system and its genetic loss of function is associated with epileptic disorders. Additionally, patients with LGI1-directed autoantibodies have frequent focal seizures as a key feature of their disease. LGI1 is composed of a Leucine-Rich Repeat (LRR) and an Epitempin (EPTP) domain. These domains are reported to interact with different members of the transsynaptic complex formed by LGI1 at excitatory synapses, including presynaptic Kv1 potassium channels. Patient-derived recombinant monoclonal antibodies (mAbs) are ideal reagents to study whether domain-specific LGI1-autoantibodies induce epileptiform activities in neurons and their downstream mechanisms. We measured the intrinsic excitability of CA3 pyramidal neurons in organotypic cultures from rat hippocampus treated with either an LRR- or an EPTP-reactive patient-derived mAb, or with IgG from control patients. We found an increase in intrinsic excitability correlated with a reduction of the sensitivity to a selective Kv1.1-channel blocker in neurons treated with the LRR mAb, but not in neurons treated with the EPTP mAb. Our findings suggest LRR mAbs are able to modulate neuronal excitability that could account for epileptiform activity observed in patients.
Autoantibodies against leucine-rich glioma-inactivated 1 (LGI1) occur in patients with encephalitis who present with frequent focal seizures and a pattern of amnesia consistent with focal hippocampal damage. To investigate whether the cellular and subcellular distribution of LGI1 may explain the localization of these features, and hence gain broader insights into LGI1’s neurobiology, we analysed the detailed localization of LGI1 and the diversity of its protein interactome, in mouse brains using patient-derived recombinant monoclonal LGI1 antibodies. Combined immunofluorescence and mass spectrometry analyses showed that LGI1 is enriched in excitatory and inhibitory synaptic contact sites, most densely within CA3 regions of the hippocampus. LGI1 is secreted in both neuronal somatodendritic and axonal compartments, and occurs in oligodendrocytic, neuro-oligodendrocytic and astro-microglial protein complexes. Proteomic data support the presence of LGI1–Kv1–MAGUK complexes, but did not reveal LGI1 complexes with postsynaptic glutamate receptors. Our results extend our understanding of regional, cellular and subcellular LGI1 expression profiles and reveal novel LGI1-associated complexes, thus providing insights into the complex biology of LGI1 and its relationship to seizures and memory loss.
The development of simple molecular assays with membrane protein receptors in a native conformation still represents a challenging task. Exosomes are extracellular vesicles which, due to their stability and small size, are suited for analysis in various assay formats. Here, we describe a novel approach to sort recombinant fully native and functional membrane proteins to exosomes using a targeting peptide. Specific binding of high affinity ligands to the potassium channel Kv1.2, the G-protein coupled receptor CXCR4, and the botulinum neurotoxin type B (BoNT/B) receptor, indicated their correct assembly and outside out orientation in exosomes. We then developed, using a label-free optical biosensor, a new method to determine the kinetic constants of BoNT/B holotoxin binding to its receptor synaptotagmin2/GT1b ganglioside (kon = 2.3 ×105 M−1.s−1, koff = 1.3 10−4 s−1), yielding an affinity constant (KD = 0.6 nM) similar to values determined from native tissue. In addition, the recombinant binding domain of BoNT/B, a potential vector for neuronal delivery, bound quasi-irreversibly to synaptotagmin 2/GT1b exosomes. Engineered exosomes provide thus a novel means to study membrane proteins for biotechnology and clinical applications.